Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05928052

Spinal Cord Stimulation to Shorten Ventilator Dependence in ARDS Patients

This is an early phase, proof-of-concept clinical trial assessing the safety and feasibility of non-invasive spinal cord stimulation to prevent respiratory muscle atrophy in mechanically ventilated ARDS patients. The investigators will recruit 10 elective surgery patients (surgery cohort) and 10 ARDS patients (ARDS cohort) for this study. A non-invasive, alpha-prototype Restore Technology stimulator using hydrogel surface electrodes will be used to stimulate the spinal cord at the cervical or thoracic level.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California, Los Angeles

Los Angeles, California, 90095, United States

Location status: Recruiting

Location contact

Daniel C Lu, MD, PhD

CONTACT

[email protected]

310-267-2975

About this study

Stimulation will be conducted in closed-loop fashion at the start of inspiratory cycle. Signal from a chest belt will be used to synchronize stimulation with ventilator and prevent interference with ventilator (see Protection of Human Subjects). Prior to treatment stimulation, mapping will be conducted at 1 Hz with electrodes placed in locations identified to be optimal in the surgery cohort. Assessment of evoked EMG responses from respiratory muscles will be conducted. Once this electrode configuration is confirmed as effective (capable of evoking EMG activity), stimulation with this configuration will be applied for treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female 18-85 years;
  • Intubated with confirmed diagnosis of ARDS (by Berlin Criteria: acute onset within one week of known insult, bilateral airspace opacities not fully explained by pleural effusions, atelectasis, and/or nodules, respiratory failure not explained by heart failure or fluid overload, PaO2/FiO2 ratio < 300); or identified as a patient admitted to the intensive care unit (ICU) after non-cardiac surgery;
  • Able to provide informed consent or available next of kin able to provide informed consent;
  • Have intact chest/lung, upper and lower extremity anatomy;
  • The neuromuscular connections between the spinal cord, diaphragm, and intercostal muscles are intact;
  • Enrollment of subject within 48 hours of intubation;
  • Able to induce evoked response of diaphragm muscle by spinal cord TES.

Exclusion criteria

  • Phrenic nerve or diaphragm pacer;
  • History of seizure disorder or on anti-epileptic medication for the treatment of seizures;
  • Compromised skin in back (neck, upper and lower back);
  • Pregnancy;
  • Implanted devices: cardiac pacemakers, implanted defibrillators, implanted neurostimulators, phrenic nerve pacers;
  • BMI greater than or equal to 35;
  • Pharmacological paralysis/neuromuscular blockade*.

Treatment and study plan

Transcutaneous Biopac Electrical Stimulator

Device

A transcutaneous electrical stimulator sends low levels of electrical current through surface hydrogel electrodes directly to the spinal cord to improve function.

Primary outcomes

  1. Recording of significant stimulation-induced adverse events (AE)

    Time frame: 1-48 months

    Although unlikely, we will record and monitor the number of stimulation-induced adverse events per case and per cohort. Our goal is to have an overall AE rate of less than 10% per cohort.

Secondary outcomes

  1. Recording of total ventilation time

    Time frame: 1-48 months

    The total time that patient is ventilated will be recorded to determine if stimulation reduces total intubation time

  2. Measurement of diaphragm thickness

    Time frame: 1-48 months

    Evidence of maintenance of diaphragm muscle thickness (in mm) by ultrasound

  3. Assessment of diaphragm and respiratory muscle EMG amplitudes

    Time frame: 1-48 months

    EMG amplitudes of diaphragm and other muscles involved in respiration (intercostals, trapezius, abdominal) will be measured at a couple time points throughout the study period to determine if stimulation can maintain muscle response.

  4. Measurement of respiratory pressure

    Time frame: 1-48 months

    Peak Inspiratory and Expiratory pressure measurements (in mm Hg) will be recorded from ventilation units to determine if stimulation maintains or improves respiratory airway pressure.

  5. Assessment of respiratory tidal volume

    Time frame: 1-48 months

    Respiratory Tidal Volume (voluntary and resting) will be recorded (in mL) to determine if stimulation assists in maintaining or improving lung capacity.

  6. Measurement of ventilator weaning time

    Time frame: 1-48 months

    Measurements of ventilator weaning time will be recorded to determine if stimulation assists in decreasing the total time from complete intubation to complete extubation.

Study contacts

Contact information is provided by the study sponsor or research team.

Daniel Lu, MD, PhD

CONTACT

[email protected]

310-825-4321

James C Leiter, MD

CONTACT

[email protected]

603-650-6130

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Registry information

Official study title

Transcutaneous Spinal Cord Stimulation to Improve Respiratory Function and Shorten Ventilator Dependence in Patients with ARDS

Important dates

Study start
2023
Primary completion
2027
Study completion
2029
First posted
Jul 3, 2023
Registry last updated
Mar 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.